Primary Series Vaccine Effectiveness Against Hospitalization (All Studies)

Primary Series Vaccine Effectiveness Against Hospitalization (All Studies) Data Table
Data as of 05/04/2022
Platform	Outcome	Age Group	Product	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	06/01/21	07/01/21	06/16/21	84.0	80.0	88.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	03/01/21	05/01/21	03/31/21	86.0	81.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	08/01/21	09/01/21	08/16/21	87.0	85.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	10/01/21	11/01/21	10/16/21	83.0	79.0	86.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	12/01/21	12/31/21	12/15/21	84.0	77.0	89.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	01/01/22	01/31/22	01/15/22	59.0	41.0	71.0	VE Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	02/01/22	03/31/22	03/01/22	47.0	25.0	63.0	VE Against Hospitalization
Overcoming (12 to 18 year olds)	Hospitalization (SARS-CoV-2-pos)	12 – 18 years	Pfizer	07/01/21	12/01/21	09/15/21	91.0	88.0	94.0	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	02/01/21	06/01/21	04/02/21	85.1	75.0	91.1	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	07/01/21	08/01/21	07/16/21	83.3	75.6	88.6	VE Against Hospitalization
SUPERNOVA	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	09/01/21	12/01/21	10/18/21	83.0	74.7	88.6	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	03/01/21	04/01/21	03/16/21	88.0	85.0	90.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	05/01/21	06/01/21	05/16/21	89.0	88.0	91.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	07/01/21	08/01/21	07/16/21	89.0	88.0	90.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	09/01/21	10/01/21	09/16/21	87.0	86.0	88.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	11/01/21	12/01/21	11/16/21	86.0	85.0	87.0	VE Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	01/01/22	1/31/2022	1/15/2022	55.0	50.0	60.0	VE Against Hospitalization

Dates are approximate

Download Data [10 KB, XLSX]

Footnotes: Vaccine effectiveness (VE) estimates for each platform are calculated with updated data using methods specified in the relevant publication(s) listed in the references section. Analyses are adjusted for factors* related to vaccination and to the likelihood of testing positive for the virus that causes COVID-19. Differences in estimates (over time or between platforms) might be due to differences in demographic, health and other characteristics of vaccinated and unvaccinated individuals, changes in immunity over time, changes in circulating virus variants, or a combination of these factors. By late June 2021, >99% of virus sequences were the Delta variant and by late January 2022, >99% of virus sequences were the Omicron variant; therefore, VE estimates from July–December 2021 represent VE for the Delta variant and VE estimates from January 2022–present represent VE for the Omicron variant. VE estimates prior to July 2021 represent a mix of circulating variants.
*All analyses adjust for time, region/study site, age, sex, race/ethnicity. VISION estimates also adjust for additional factors related to a person’s likelihood of vaccination.
Horizontal lines indicate average vaccine effectiveness over the months indicated; vertical lines indicate the 95% confidence interval around the vaccine effectiveness point estimate.
As of December 17, 2021, the SUPERNOVA platform has ended and will not be providing additional estimates.